Articlenpj biomedical innovations2026
Development and early feasibility testing of machine-learning algorithms to non-invasively assess hemoglobin levels.
Article in npj biomedical innovations, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The HeMonitor study evaluated the feasibility and accuracy of non-invasive hemoglobin (Hb) assessment using image-based techniques and machine learning in patients with hematologic malignancies. A total of 367 patients with hematologic malignancies and 184 healśśthy donors were enrolled, with fingernail and eyelid photographs collected and analyzed using Light Gradient-Boosting Machine (LightGBM) regression models. The best-performing model achieved a residual standard deviation of ±1.02 mmol/L for Hb prediction. Our framework further explored a two-stage concept combining (i) a non-invasive image-based Hb predictor and (ii) a post hoc, rule-basśed corridor aggregation layer integrating EORTC Global Health and Fatigue categories. This exploratory layer was designed to contextualize Hb estimates with patient-reported symptom burden and well-being. Visual analyses suggested that lower Hb levels were generally associated with impaired quality-of-life measures, consistent with the known clinical burden of anemia. Within the QoL subset, the integrated framework showed encouraging concordance with clinician assessments, particularly in borderline Hb ranges. These findings support the feasibility of combining digital biomarkers with patient-reported outcomes for future patient-centered home monitoring strategies, while prospective validation remains necessary.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.